Medicare is getting into the weight-loss game, at least for a little while. Starting July 1, eligible Part D enrollees will be able to get certain GLP-1 weight-loss drugs for a flat $50 monthly copay under a short-term test program called the Medicare GLP-1 Bridge. The demonstration runs through December 31, 2027 and is meant to serve as a temporary pathway while federal officials hash out longer-term coverage rules. Access will be tightly controlled by body-mass index thresholds and specific cardiac, kidney, or metabolic conditions, and prescribers and pharmacies will have to follow new prior-authorization steps before any prescriptions are filled.
CMS rolled out the Bridge in a May press release and said the $50 copay is meant to bring more consistency and affordability to these high-profile medications for Medicare beneficiaries. The agency plans to use centralized processing for approvals, claims adjudication, and pharmacy payments, and is urging people with Part D to talk with their clinicians about whether a GLP-1 makes sense for them, according to CMS.
Who qualifies
The Bridge is not a blanket weight-loss benefit. To qualify, a beneficiary must be prescribed a GLP-1 specifically to reduce excess body weight and must meet detailed clinical criteria; age alone does not open the door.
CMS guidance says beneficiaries must meet one of several paths: a body mass index (BMI) of at least 35; or a BMI of 30 or higher plus heart failure, uncontrolled hypertension, or chronic kidney disease; or a BMI of 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease, as detailed by CMS. People who already receive GLP-1s through their Part D plans for diabetes or other currently covered uses are excluded from the Bridge.
Which drugs are covered
The new benefit does not cover every GLP-1 on the market. The Bridge is limited to specific formulations: all forms of Wegovy (both injections and tablets), the KwikPen formulation of Zepbound, and Foundayo tablets, according to KFF. Manufacturers agreed to a negotiated net price of about $245 per month for each of these medicines. Pharmacies will collect the flat $50 from beneficiaries and then submit claims to a central processor to be reimbursed for the difference.
How it will work
Operationally, CMS is keeping the Bridge outside the usual Part D payment machinery and will lean on a single central processor to handle prior authorizations, claims adjudication, and pharmacy payments. That setup puts pharmacies squarely in the middle of the rollout.
The National Association of Chain Drug Stores says pharmacies will receive fact sheets and take part in CMS webinars ahead of the July launch, and that pharmacists will be central to routing claims correctly and triggering the new prior-authorization workflows, as noted by NACDS.
What beneficiaries should know
There is a big fine print item: the $50 monthly copay will not count toward a beneficiary’s Part D deductible or out-of-pocket threshold, and Low-Income Subsidy discounts will not apply. Those details could make the benefit a tougher lift for some low- and modest-income seniors, according to KFF.
CMS has extended the Bridge through December 31, 2027 while the longer-term BALANCE model for Part D remains delayed. That leaves the program’s fate beyond 2027 up in the air. The Medicare Rights Center recommends that beneficiaries speak with their prescribers and review available FAQs before they decide whether to apply.
In context
Coverage of the Bridge has spread quickly. WATE was first to run a Nexstar Media Wire dispatch on the announcement, and a separate report on employers and insurers tightening or tweaking GLP-1 benefits as coverage widens came from Cigna yanks Wegovy perk, as reported by WATE and Cigna yanks Wegovy perk. Anyone with Part D who thinks they might qualify for the Bridge should double-check with their clinician and their plan before the July 1 rollout.
